Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic
References (24)
- et al.
Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
Am J Med
(1989) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized clinical trials
Arch Intern Med
(1994)- et al.
Preventing stroke in patients with atrial fibrillation
JAMA
(1999) - et al.
Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation
J Gen Intern Med
(1996) - et al.
Screening for atrial fibrillation in primary care
Heart
(1998) Stroke prevention in atrial fibrillation study Final results
Circulation
(1991)- et al.
A method to determine the optimal intensity of oral anticoagulant therapy
Thromb Haemost
(1993) - et al.
The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial
Arch Intern Med
(1991) - et al.
The risk for and severity of bleeding complications in elderly patients treated with warfarin
Ann Intern Med
(1996) - et al.
Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans
Clin Pharmacol Ther
(1987)
Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission
Stroke
Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness
BMJ
Cited by (50)
Neurological complications of cardiovascular drugs
2021, Handbook of Clinical NeurologyNew strategies for effective treatment of vitamin K antagonist-associated bleeding
2015, Journal of Thrombosis and HaemostasisPhysical activity and risk of bleeding in elderly patients taking anticoagulants
2015, Journal of Thrombosis and HaemostasisFiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: A single centre, double-blind, randomised, non-inferiority trial
2015, The Lancet HaematologyCitation Excerpt :We also calculated the variance growth rate as an indicator of INR variability between tests (B1 method).15 To calculate the non-inferiority margin, we used data from previous prospective studies16–19 in patients with mixed indications for anticoagulation, with an INR target of 2–3, monitored and dosed by our anticoagulation management centre. On the basis of these studies, we used an expected 3% annual thromboembolism incidence and a non-inferiority margin of 2·5%.
Evaluation of telephone assessment in stroke and TIA recurrence
2012, NeurologiaOral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
2012, ChestCitation Excerpt :Rates of thromboembolism with UC were not reported except in two studies in which the event rates were 6.2% and 8.1% per patient-year. Similarly, retrospective and prospective cohort studies of care provided by an AMS reported rates of major hemorrhage or thrombosis ranging from 1.4% to 3.3% and 0.7% to 6.3% per patient-year of therapy, respectively.164,170,207–210 Three retrospective comparative studies using a before-and-after design of patients managed by UC or an AMS reported significant improvements in the outcomes of hemorrhage or thrombosis with AMS-directed care.211–213